Esperion Therapeutics, Inc. (ESPR) Stake Increased by Candriam Luxembourg SCA

If the $69.64 price target is reached, the company will be worth $150.66 million more. The firm purchased 51,997 shares of the biopharmaceutical company's stock, valued at approximately $2,606,000. Esperion Therapeutics Inc has a 1-year low of $9.40 and a 1-year high of $48.21. It has outperformed by 117.05% the S&P500. Six equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Therefore 93% are positive. Esperion Therapeutics had 47 analyst reports since July 28, 2015 according to SRatingsIntel. Barclays Capital upgraded Trevena, Inc. JMP Securities maintained the stock with "Market Outperform" rating in Wednesday, March 9 report. Esperion Therapeutics now has a consensus rating of "Buy" and a consensus price target of $58.92. The firm has "Outperform" rating given on Tuesday, March 29 by FBR Capital. The stock has "Buy" rating by Stifel Nicolaus on Thursday, February 25. "(NASDAQ:ESPR) Acquired by Columbus Circle Investors" was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. The stock of Trevena, Inc. (NASDAQ:ESPR). Deutsche Bancorporation Ag owns 167,872 shares or 0.01% of their United States portfolio. Oppenheimer has "Buy" rating and $800 target.

Trevena, Inc., a biopharmaceutical company, develops various therapies based on breakthrough science to benefit patients and healthcare providers confronting serious medical conditions. It now has negative earnings. The company had a trading volume of 415,100 shares, compared to its average volume of 1,029,116. Trevena, Inc. (NASDAQ:TRVN) has declined 52.53% since December 2, 2016 and is downtrending. It has underperformed by 4.68% the S&P500. Voloridge Management Limited Liability Corp has 0.12% invested in Esperion Therapeutics, Inc. The stock's market cap is $750.83 million. The Company's lead product candidate is Bempedoic acid, an inhibitor of ATP-citrate lyase that reduces cholesterol biosynthesis that is in Phase III long-term safety and tolerability study.

With 577,600 avg volume, 7 days are for Esperion Therapeutics Incorporated (NASDAQ:ESPR)'s short sellers to cover ESPR's short positions. Therefore 61% are positive. Baidu had 55 analyst reports since July 28, 2015 according to SRatingsIntel. The firm earned "Neutral" rating on Monday, November 14 by Citigroup. The company was maintained on Wednesday, June 29 by Citigroup. The company was maintained on Tuesday, September 29 by Chardan Capital Markets. On Wednesday, June 29 the stock rating was downgraded by Barclays Capital to "Equal-Weight". Needham upgraded the stock to "Buy" rating in Monday, August 10 report. On Monday, August 31 the stock rating was maintained by Chardan Capital Markets with "Sell". (NASDAQ:ESPR) has "Buy" rating given on Wednesday, October 18 by Cowen & Co. Finally, Jefferies Group LLC reiterated a "buy" rating and set a $85.00 target price on shares of Esperion Therapeutics in a research report on Monday, August 21st. The firm has "Buy" rating given on Monday, October 26 by Lake Street.

Investors sentiment decreased to 1.22 in 2017 Q2. Its down 0.52, from 1.74 in 2017Q1. Iguana Healthcare Management LLC lifted its holdings in Esperion Therapeutics by 50.0% in the 3rd quarter. 26 funds opened positions while 34 raised stakes.


On average, analysts expect that Esperion Therapeutics will report full year earnings of ($7.21) per share for the current financial year, with EPS estimates ranging from ($7.63) to ($6.54). (NASDAQ:ESPR) for 7,008 shares. Elkfork Partners LLC owned about 0.06% of Esperion Therapeutics worth $475,000 at the end of the most recent quarter.

Several brokerages recently commented on ESPR. The Group One Trading Lp holds 10,810 shares with $500,000 value, down from 58,312 last quarter. (NASDAQ:ESPR). State Of Wisconsin Board has 11,000 shares for 0% of their portfolio.

Esperion Therapeutics, Inc is a lipid management company. ESPR's SI was 4.11 million shares in December as released by FINRA. Northern Tru Corporation reported 434,913 shares.

COPYRIGHT VIOLATION WARNING: "Esperion Therapeutics, Inc". (NASDAQ:ESPR). 8,376 were reported by Wellington Mgmt Llp. Maryland-based Proshare Advisors Limited Com has invested 0.01% in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Gam Ag reported 0.15% of its portfolio in Esperion Therapeutics, Inc. (NASDAQ:ESPR) news were published by: Prnewswire.com which released: "Biotech Stocks on Investors' Radar - Curis, Egalet, Esperion Therapeutics ..." on November 02, 2017, also Streetinsider.com with their article: "Esperion Therapeutics (ESPR) Commences Pivotal Phase 3 Study for the Bempedoic ..." published on November 06, 2017, Fool.com published: "Here's What's Pushing Up Esperion Therapeutics Inc".

Related:

Comments

Latest news

Football Moment that Left us Speech-Less.
With an 11- 0 score at the end of the game, Germany started the Shanghai Women’s World Cup with a world record win. Women’s World Cup 2007 Germanys women’s team opened the World Cup with a bang against Argentina.

Ben Stokes out cheaply on debut for Canterbury
Stokes has been mostly silent since his arrival in New Zealand but his short-term deal has attracted criticism across the Tasman Sea.

NetEase (NTES) Downgraded by ValuEngine to Hold
The Company operates through three segments: Online Game Services; Advertising Services, and E-mail, E-commerce and Others. The firm has a market capitalization of $43,422.92, a P/E ratio of 21.89, a P/E/G ratio of 1.84 and a beta of 0.92.

How Analysts Rated Navios Maritime Midstream Partners LP (NYSE:NAP) Last Week?
ValuEngine downgraded shares of Navios Maritime from a hold rating to a sell rating in a research note on Friday, September 1st. Bloom Tree Partners Llc decreased Sherwin Williams Co (NYSE:SHW) stake by 34,151 shares to 103,875 valued at $36.46M in 2017Q2.

Capstead Mortgage (CMO) Upgraded to Buy at ValuEngine
Headlines about Anworth Mortgage Asset (NYSE:ANH) have trended very positive this week, Alpha One Sentiment reports. The business had revenue of $57.44 million for the quarter, compared to analysts' expectations of $24.10 million.

Other news